Iambic Therapeutics launched into public markets with a $150 million IPO to accelerate clinical development of an oncology pipeline built from internally discovered programs. The company described an AI-enabled approach aimed at improving discovery efficiency and translating molecular findings into candidate development. In connection with the offering, Iambic said it will allocate IPO proceeds toward clinical development activities across its cancer drug portfolio. The company also reported R&D alliances with larger partners, including Bayer and AbbVie, positioned to support preclinical development and discovery validation. The IPO is part of a broader resurgence in early-stage AI-first biotechs seeking capital for faster candidate progression. For the biotech sector, the immediate watch item is whether AI-discovered candidates can demonstrate clinical differentiation as they move from early discovery into human studies. The market signal is clear: investors are still underwriting AI oncology pipelines—provided teams can convert computational leads into clinical outcomes.